State Street’s iRadimed IRMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $19.7M | Buy |
204,528
+11,576
| +6% | +$1.16M | ﹤0.01% | 2246 |
|
|
2025
Q4 | $18.8M | Buy |
192,952
+5,713
| +3% | +$490K | ﹤0.01% | 2302 |
|
|
2025
Q3 | $13.3M | Buy |
187,239
+9,850
| +6% | +$656K | ﹤0.01% | 2468 |
|
|
2025
Q2 | $10.6M | Buy |
177,389
+1,707
| +1% | +$93.6K | ﹤0.01% | 2566 |
|
|
2025
Q1 | $9.22M | Buy |
175,682
+1,244
| +0.7% | +$69.9K | ﹤0.01% | 2574 |
|
|
2024
Q4 | $9.59M | Buy |
174,438
+8,905
| +5% | +$469K | ﹤0.01% | 2652 |
|
|
2024
Q3 | $8.32M | Sell |
165,533
-3,383
| -2% | -$156K | ﹤0.01% | 2712 |
|
|
2024
Q2 | $7.42M | Buy |
168,916
+12,942
| +8% | +$550K | ﹤0.01% | 2742 |
|
|
2024
Q1 | $6.86M | Buy |
155,974
+6,237
| +4% | +$276K | ﹤0.01% | 2788 |
|
|
2023
Q4 | $7.2M | Buy |
149,737
+15,273
| +11% | +$642K | ﹤0.01% | 2754 |
|
|
2023
Q3 | $5.97M | Buy |
134,464
+3,000
| +2% | +$139K | ﹤0.01% | 2841 |
|
|
2023
Q2 | $6.28M | Buy |
131,464
+7,183
| +6% | +$324K | ﹤0.01% | 2888 |
|
|
2023
Q1 | $4.89M | Buy |
124,281
+2,870
| +2% | +$104K | ﹤0.01% | 3000 |
|
|
2022
Q4 | $3.43M | Buy |
121,411
+521
| +0.4% | +$14.9K | ﹤0.01% | 3202 |
|
|
2022
Q3 | $3.63M | Buy |
120,890
+799
| +0.7% | +$27.8K | ﹤0.01% | 3212 |
|
|
2022
Q2 | $4.08M | Buy |
120,091
+6,639
| +6% | +$238K | ﹤0.01% | 3195 |
|
|
2022
Q1 | $5.09M | Buy |
113,452
+10,950
| +11% | +$506K | ﹤0.01% | 3169 |
|
|
2021
Q4 | $4.74M | Buy |
102,502
+3,014
| +3% | +$122K | ﹤0.01% | 3268 |
|
|
2021
Q3 | $3.34M | Buy |
99,488
+3,050
| +3% | +$104K | ﹤0.01% | 3440 |
|
|
2021
Q2 | $2.84M | Buy |
96,438
+4,993
| +5% | +$138K | ﹤0.01% | 3482 |
|
|
2021
Q1 | $2.36M | Sell |
91,445
-1,949
| -2% | -$46.6K | ﹤0.01% | 3370 |
|
|
2020
Q4 | $2.13M | Buy |
93,394
+6,636
| +8% | +$153K | ﹤0.01% | 3346 |
|
|
2020
Q3 | $1.85M | Buy |
86,758
+13,976
| +19% | +$314K | ﹤0.01% | 3231 |
|
|
2020
Q2 | $1.69M | Buy |
72,782
+6,586
| +10% | +$141K | ﹤0.01% | 3243 |
|
|
2020
Q1 | $1.41M | Buy |
66,196
+1,301
| +2% | +$31K | ﹤0.01% | 3204 |
|
|
2019
Q4 | $1.52M | Buy |
64,895
+7,357
| +13% | +$172K | ﹤0.01% | 3325 |
|
|
2019
Q3 | $1.21M | Buy |
57,538
+2,136
| +4% | +$43.6K | ﹤0.01% | 3365 |
|
|
2019
Q2 | $1.13M | Buy |
55,402
+720
| +1% | +$17K | ﹤0.01% | 3398 |
|
|
2019
Q1 | $1.54M | Sell |
54,682
-5,403
| -9% | -$141K | ﹤0.01% | 3246 |
|
|
2018
Q4 | $1.47M | Buy |
60,085
+3,098
| +5% | +$83.2K | ﹤0.01% | 3231 |
|
|
2018
Q3 | $2.12M | Buy |
56,987
+24,369
| +75% | +$658K | ﹤0.01% | 3223 |
|
|
2018
Q2 | $677K | Buy |
+32,618
| New | +$577K | ﹤0.01% | 3441 |
|
|
2017
Q2 | – | Sell |
-67,001
| Closed | -$595K | – | 3718 |
|
|
2017
Q1 | $595K | Buy |
67,001
+22,700
| +51% | +$210K | ﹤0.01% | 3359 |
|
|
2016
Q4 | $492K | Buy |
44,301
+326
| +0.7% | +$3.51K | ﹤0.01% | 3391 |
|
|
2016
Q3 | $747K | Buy |
43,975
+1,893
| +4% | +$35.1K | ﹤0.01% | 3242 |
|
|
2016
Q2 | $917K | Buy |
42,082
+10,609
| +34% | +$191K | ﹤0.01% | 3293 |
|
|
2016
Q1 | $603K | Buy |
31,473
+4,900
| +18% | +$93.8K | ﹤0.01% | 3321 |
|
|
2015
Q4 | $744K | Buy |
26,573
+8,260
| +45% | +$234K | ﹤0.01% | 3271 |
|
|
2015
Q3 | $445K | Buy |
18,313
+5,084
| +38% | +$122K | ﹤0.01% | 3357 |
|
|
2015
Q2 | $308K | Buy |
+13,229
| New | +$242K | ﹤0.01% | 3437 |
|
Other funds holding IRMD
CCM
VCM
NTCM
State Street's IRMD Position: Q1 2026 in Review
State Street increased its iRadimed (IRMD) stake by 6% in Q1 2026, buying an estimated $1.16M and bringing the position to 204,528 shares worth $19.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2246.
State Street first reported a position in IRMD in Q2 2015 and has held it in 40 quarters since. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.
- State Street held 204,528 shares of iRadimed worth $19.7M as of Q1 2026.
- State Street bought 11,576 iRadimed shares in Q1 2026, an estimated $1.16M.
- iRadimed made up ﹤0.01% of State Street's portfolio in Q1 2026, its #2246 holding.
- State Street first reported a position in iRadimed in Q2 2015 and has held it in 40 quarters since.
- 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.
Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.